Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tetrahydrocannabinol,Cannabidiol
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tilray Medical Granted Approval to Introduce Third Medical Cannabis Product in Portugal
Details : Tilray's oral solution THC10:CBD10 medical cannabis extract is approved for medical use in Portugal for various medical conditions including chronic pain, nausea and spasticity.
Brand Name : THC10:CBD10
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 24, 2024
Lead Product(s) : Tetrahydrocannabinol,Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : IntelGenx
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The agreement aims for the co-development and commercialization of cannabinoid-infused VersaFilm® products, including CBD VersaFilm (cannabinoid), a unique drug opportunity for the treatment of neurodegenerative diseases of the brain.
Brand Name : CBD VersaFilm
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 06, 2023
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : IntelGenx
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tilray Medical Launches New Products and ‘CannaPoints’ Program to Support Patients Across Canada
Details : Tilray Medical, has released new medical cannabis products, under Tilray and Aphria brands and launched CannaPoints, a new program designed to support patients through their medical cannabis journey.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 25, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Sleep
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tilray Medical Launches Sleep-Oriented CBN Night Oil for Medical Cannabis Patients in Canada
Details : CBN, or cannabinol, is derived from THC and is known to help improve the duration and quality of sleep, CBN-dominant oil is carefully formulated with 30mg CBN per mL and 10mg THC per mL (in a 50mL bottle).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 07, 2022
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Sleep
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Aphria
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Company's Fast-Acting Oral Strips contain Cannabinoids absorb directly into the bloodstream provide patients with a fast-acting, convenient, and precise dosing experience for relief from a range of conditions.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 02, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Aphria
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?